SGLT2抑制和脂肪组织代谢:当前前景和前景
Cassandra Morciano1,2,3, Shawn Gugliandolo1,2, Umberto Capece1,2
1Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
-葡萄糖共载体2抑制剂 (SGLT2i) 通过影响脂肪组织,改善2型糖尿病患者的心血管健康. 这些SGLT2抑制剂减少脂肪量,增强新陈代谢健康,提供新的治疗途径.
科学领域:
- 代谢研究的研究.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共载体2抑制剂 (SGLT2i) 是2型糖尿病 (T2DM) 管理的关键.
- 它们对心血管的益处超出了血糖控制范围,涉及代谢效应.
- 新兴研究强调SGLT2i对脂肪组织的影响.
研究的目的:
- 审查SGLT2抑制剂对脂肪组织的影响.
- 阐明SGLT2i在代谢健康中的作用.
- 探索SGLT2i在T2DM治疗中的潜力,不仅仅是降低葡萄糖.
主要方法:
- 在体外研究中的研究.
- 鼠类模型的模型.
- 对人类临床数据和心血管结局试验的分析.
主要成果:
- SGLT2i 减少脂肪质量和脂肪细胞大小.
- 观察到白色脂肪组织色基因的升级和脂肪酸氧化增强.
- 在脂肪组织中改善了氧化应激和代谢健康参数.
结论:
- SGLT2i对脂肪组织产生显著影响,有助于改善代谢.
- 这些脂肪组织影响可能部分解释了T2DM患者心血管方面的好处.
- 通过多方面的代谢作用,SGLT2i有望改变T2DM治疗策略.
更多相关视频
06:08Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
09:41Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
